Previously, it was shown that inhibition of IL-36 signaling by treatment with an anti-IL36R antibody or the IL-36RA antagonist partially prevents the development of IMQ- or IL-36-mediated psoriasis in mice (30–32). Here, IL1RL2 is linked to psoriasis.